Characteristics of Patient Demographics and Accessibility to Clinical Trial Locations for Invasive Fungal Infections
Overview
This study investigates the demographics and accessibility of clinical trial sites for invasive fungal infections (IFIs) in the U.S., revealing significant disparities in access based on socioeconomic and geographic factors. The findings highlight that trial sites are predominantly located in urban areas, potentially underrepresenting rural populations with significant IFI burdens.
Background
Access to clinical trials is crucial for advancing treatment options, yet disparities exist, particularly affecting socioeconomically disadvantaged and rural populations. This study addresses the lack of comprehensive examination of access to IFI trials, which is essential given the increasing incidence of these infections and their varied epidemiology across different regions. Understanding these disparities can inform strategies to improve access and representation in clinical research.
Data Highlights
Trial Type
Number of Trials
Unique Sites
Median Enrollment
Treatment
21
244
88 (31-199)
Prophylaxis
6
32
Not specified
Key Findings
27 antifungal clinical trials identified, with 21 for treatment and 6 for prophylaxis.
99.3% of the population around treatment sites and 98.6% around prophylaxis sites resided in metropolitan areas.
Higher representation of racial minority groups in prophylaxis site catchments compared to the U.S. population.
46.8% of residents in treatment areas had fewer vehicles than household members.
Substantial underrepresentation of rural populations in trial catchments, with only 0.6% and 0.2% of surrounding populations classified as rural for treatment and prophylaxis sites, respectively.
Clinical Implications
The concentration of clinical trial sites in urban areas may limit access for rural populations who are at higher risk for invasive fungal infections. Clinicians should be aware of these disparities when considering treatment options and advocating for their patients' participation in clinical trials.
Conclusion
This study underscores the need for increased awareness of access disparities in clinical trials for invasive fungal infections, particularly for rural and socioeconomically disadvantaged populations. Addressing these disparities is essential for ensuring equitable representation in clinical research.
